Bibliography
- WILLETT CG, BOUCHER E, DI TOMASO E et al.: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. (2004) 10:145–147.
- DVORAK HF: Vascular permeability factor/endothelial growth factor, a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. Clin. Oncol (2002) 20:4368–4380.
- HATTORI K, HEISSIG B, WU Y, DIAS S et al.: Placental growth factor reconstitutes hematopoiesis by recruiting VE GERI+ stem cells from bone-marrow microenvironment. Nat. Med. (2002) 8:841–849.
- KABBINAVAR F, HURWITZ HI, FEHRENBACHER L et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol (2003) 21:60–65.
- YUAN F, CHEN Y, DELLIAN M et al.:Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. USA 93:14765–14770.
- LEE C-G, HEIJY M, DI TOMASO E et al.: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. (2000) 60:5565–5570.
- GORDON MS, MARGOLIN K, TALPAZ M et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. Clin. OncoL (2001) 19:843–850.
- COBLEIGH MA, LANGMUIR VK, SLEDGE GW et al. A Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. &min. Oncol (2003) 30(5 Suppl. 16):117–124.
- YANG JC, HAWORTH L, SHERRY P.M et al: A randomized trial of bevacizumab, and anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl. J. Med. (2003) 349:427–434.
- McCARTHY M: Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet (2003) 361:1959.
- MANCUSO P, BURLINI A, PRUNERI G et al.: Resting and activated endothelial cells are increased in the peripheral blood of cancer cells. Blood (2001) 97:3658-3661. Affiliation Sheila A Doggrell PhD DSc Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand E-mail: [email protected]